Holen Sie sich die Stockscreener-App
0.42
0.67%
-0.001
Schlusskurs vom Vortag:
$0.419
Offen:
$0.41
24-Stunden-Volumen:
139.52K
Relative Volume:
0.61
Marktkapitalisierung:
$8.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.58M
KGV:
-0.3652
EPS:
-1.15
Netto-Cashflow:
$-9.80M
1W Leistung:
+10.49%
1M Leistung:
+1.91%
6M Leistung:
-78.54%
1J Leistung:
-81.00%
1-Tages-Spanne:
$0.41
$0.4281
1-Wochen-Bereich:
$0.375
$0.4304
52-Wochen-Spanne:
$0.30
$3.325
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Firmenname
Acurx Pharmaceuticals Inc
Sektor
Branche
Telefon
917-533-1469
Adresse
259 LIBERTY AVENUE, STATEN ISLAND
Vergleichen Sie ACXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.42 | 8.13M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.90 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.00 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
633.00 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
247.69 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
Acurx CEO to Reveal Phase 3 Strategy for Breakthrough C. Difficile Antibiotic at Major Healthcare Conference - Stock Titan
Acurx Pharmaceuticals secures patent in India for antibiotics By Investing.com - Investing.com Canada
Acurx Pharmaceuticals secures patent in India for antibiotics - Investing.com
Acurx Expands Global Patent Portfolio: Phase 3-Ready Drug Targets MRSA, Anthrax, and Superbugs - Stock Titan
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors - Yahoo Finance
Lobbying Update: $20,000 of ACURX PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach - Corsicana Daily Sun
Press Release Distribution & PR Platform - ACCESS Newswire
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Acurx Pharmaceuticals announces resale of 8.4M shares - MSN
10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 - Insider Monkey
ACXP stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
Acurx Pharmaceuticals Inc (ACXP) Q4 2024 Earnings Call Highlights: Advancing Antibiotic Trials ... By GuruFocus - Investing.com Canada
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Issues Positive Forecast for ACXP Earnings - Defense World
FY2029 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2024 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports 2024 Results and Advances Trials - TipRanks
Acurx Pharmaceuticals’ Optimistic Earnings Call Highlights Clinical Progress - TipRanks
Earnings call transcript: Acurx Pharmaceuticals Q4 2024 sees narrower EPS loss - Investing.com Canada
ACXP stock touches 52-week low at $0.43 amid market challenges - Investing.com UK
Acurx Pharmaceuticals, Inc Full Year Loss Narrows - Nasdaq
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Yahoo Finance
Earnings Scheduled For March 18, 2025 - Benzinga
Acurx Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Increases By 112.2% - The AM Reporter
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP - Milton Daily Standard
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Growth in Short Interest - Defense World
Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Acurx Pharmaceuticals Announces Closing of $1.1 Million Registered Direct Offering -March 10, 2025 at 05:37 pm EDT - MarketScreener
ACXPAcurx Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - Stock Titan
Dow Dips Over 250 Points; Genesco Shares Plunge After Q4 Results - Benzinga
Why Acurx Pharmaceuticals (ACXP) Shares Are Down 30% - Benzinga
Acurx Pharmaceuticals Launches $1.1 Million Registered Direct Offering; Shares Fall -March 07, 2025 at 10:07 am EST - Marketscreener.com
Nasdaq Gains 100 Points; US Economy Adds Fewer Jobs Than Projected - Benzinga
Acurx Pharmaceuticals stock sinks on $1.1M direct offering - MSN
Acurx Pharmaceuticals Announces $1.1 Million Registered Direct Offering -March 07, 2025 at 08:14 am EST - Marketscreener.com
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decrease in Short Interest - Defense World
ACXP stock touches 52-week low at $0.66 amid market challenges - Investing.com
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics - Yahoo Finance
Can Acurx's Antibiotic Revolutionize C. Difficile Treatment? New Microbiome Data Suggests Yes - Stock Titan
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update - Yahoo Finance
Biotech Alert: Searches spiking for these stocks today - TipRanks
Acurx’s ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals Advances To Phase 3 Trials For C. Difficile Infection, Stock Down - Nasdaq
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the - Digital More
Finanzdaten der Acurx Pharmaceuticals Inc-Aktie (ACXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acurx Pharmaceuticals Inc-Aktie (ACXP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
| LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
| Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
| DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
| DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
1.36%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):